His main research concerns Cancer research, Pathology, Internal medicine, Immunohistochemistry and Cancer. Peter Schirmacher has researched Cancer research in several fields, including Carcinogenesis, Gene silencing and Immunology. The study incorporates disciplines such as Cirrhosis, Hepatitis C, Immune system and Adenocarcinoma in addition to Pathology.
His studies deal with areas such as Gastroenterology, Endocrinology and Oncology as well as Internal medicine. His work in the fields of Cancer, such as Colorectal cancer, intersects with other areas such as Context. His studies in Hepatocellular carcinoma integrate themes in fields like RNA and Hepatitis B virus.
Peter Schirmacher spends much of his time researching Cancer research, Pathology, Internal medicine, Oncology and Cancer. His Cancer research research incorporates themes from Carcinogenesis, Apoptosis and Immunology. His Pathology study frequently intersects with other fields, such as Adenocarcinoma.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Endocrinology.
The scientist’s investigation covers issues in Cancer research, Internal medicine, Oncology, Pathology and Computational biology. His Liver cancer and Hepatocellular carcinoma investigations are all subjects of Cancer research research. His Internal medicine study frequently links to adjacent areas such as Gastroenterology.
Peter Schirmacher works mostly in the field of Oncology, limiting it down to topics relating to Primary tumor and, in certain cases, Malignancy, as a part of the same area of interest. He studies Immunohistochemistry which is a part of Pathology. His Computational biology study incorporates themes from Gene panel, In silico and Molecular diagnostics.
Peter Schirmacher mostly deals with Internal medicine, Pathology, Cancer research, Oncology and Computational biology. His Internal medicine research focuses on Gastroenterology and how it connects with Odds ratio. His Pathology research is multidisciplinary, incorporating elements of KRAS and Molecular pathology.
The concepts of his Cancer research study are interwoven with issues in Gene expression profiling, Immune system, Immunotherapy, DNA mismatch repair and RNA interference. His Immunotherapy study which covers Tumor necrosis factor alpha that intersects with Hepatocellular carcinoma. His Oncology research includes themes of Tyrosine kinase, Primary tumor and DNA profiling.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle;Alejandro Forner;Josep M. Llovet;Vincenzo Mazzaferro.
Journal of Hepatology (2018)
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Tae-Won Kang;Tetyana Yevsa;Norman Woller;Lisa Hoenicke.
The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival
Arne Warth;Thomas Muley;Michael Meister;Albrecht Stenzinger.
Journal of Clinical Oncology (2012)
Most pancreatic cancer resections are R1 resections.
Irene Esposito;Irene Esposito;Jörg Kleeff;Jörg Kleeff;Frank Bergmann;Caroline Reiser;Caroline Reiser.
Annals of Surgical Oncology (2008)
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B
Karsten Wursthorn;Marc Lutgehetmann;Maura Dandri;Tassilo Volz.
MicroRNA gene expression profile of hepatitis C virus–associated hepatocellular carcinoma
Heike Varnholt;Uta Drebber;Falko Schulze;Inga Wedemeyer.
An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer
Lars Zender;Wen Xue;Johannes Zuber;Camile P. Semighini.
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment
Simon Reiss;Ilka Rebhan;Perdita Backes;Ines Romero-Brey.
Cell Host & Microbe (2011)
Dysregulation of growth factor signaling in human hepatocellular carcinoma.
K Breuhahn;T Longerich;P Schirmacher.
Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation
Aaheli Roy Choudhury;Zhenyu Ju;Meta W. Djojosubroto;Andrea Schienke.
Nature Genetics (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: